CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.21 and traded as low as $0.1952. CytoDyn shares last traded at $0.21, with a volume of 3,226,470 shares trading hands.
CytoDyn Trading Up 1.8%
The firm has a market cap of $306.88 million, a P/E ratio of -10.69 and a beta of 1.24. The stock has a 50 day simple moving average of $0.20 and a 200-day simple moving average of $0.26.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on developing leronlimab, an investigational monoclonal antibody designed to target and block CCR5, a receptor involved in immune-cell signaling. The company is headquartered in Vancouver, Washington.
Leronlimab has been studied as a potential treatment for HIV infection and other diseases in which CCR5 may play a role. CytoDyn has also explored the compound in oncology and inflammatory conditions, including certain forms of cancer and other immune-related disorders.
Recommended Stories
- Five stocks we like better than CytoDyn
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
